Abstract

Conmed will release its first-quarter 2026 financial results on April 29, 2026 Post Market, with street models pointing to roughly 310.51 million US dollars of revenue and adjusted EPS of 0.82, while investors weigh mixed growth and margin signals into the print.

Market Forecast

Consensus for Conmed’s current quarter centers on revenue of 310.51 million US dollars, down 0.92% year over year, adjusted EPS of 0.82, up 0.93% year over year, and EBIT of 38.21 million US dollars, down 3.54% year over year; explicit forecasts for gross margin and net profit margin are not available, and company-issued quarterly guidance has not been provided. The business mix remains anchored in two operating pillars that investors track for momentum and visibility—General Surgery and Orthopedic Surgery—where product mix and installed base utilization are expected to shape profitability in the near term. Within that mix, General Surgery remains the most closely watched growth engine; in the prior quarter it contributed approximately 217.21 million US dollars and, at the total-company level, revenue grew 7.88% year over year, setting a baseline against which this quarter’s trajectory will be assessed.

Last Quarter Review

Conmed’s previous quarter delivered revenue of 373.20 million US dollars (up 7.88% year over year), a 47.26% gross profit margin, GAAP net profit attributable to shareholders of 16.74 million US dollars for a 4.49% net profit margin, and adjusted EPS of 1.43 (up 6.72% year over year). A key highlight was outperformance versus models: revenue exceeded expectations by 6.40 million US dollars and adjusted EPS beat by 0.11, aided by operational execution and cost discipline. Main business performance reflected a stable mix, with General Surgery generating approximately 217.21 million US dollars and Orthopedic Surgery contributing about 155.99 million US dollars; at the company level, total revenue advanced 7.88% year over year, supporting healthy drop-through to adjusted earnings.

Current Quarter Outlook

Main business trajectory and profitability mix

Into the first quarter, models indicate a modest year-over-year revenue decline of 0.92% to 310.51 million US dollars and a slight uptick in adjusted EPS to 0.82, implying some cushion from mix, productivity, and operating expense control. The step down from the prior quarter’s 373.20 million US dollars is consistent with normal sequential ebb and flow, and the EBIT estimate of 38.21 million US dollars, down 3.54% year over year, suggests a measured compression in operating leverage that investors will parse against any commentary on price, volume, and cost inputs. With the prior quarter’s gross margin at 47.26%, the street appears to be embedding broadly stable conversion dynamics this quarter, absent a formal margin guide; any deviation from this run-rate, positive or negative, will likely steer post-report narrative as much as the headline growth rate.

Management’s full-year framework, communicated at the end of January, calls for revenue of 1.35–1.38 billion US dollars and adjusted EPS of 4.30–4.45. At the midpoint of revenue guidance, the implied average quarterly run-rate is roughly 340 million US dollars, which is higher than the 310.51 million US dollars modeled for the first quarter. That gap implicitly assumes acceleration later in the year through volume growth, incremental pricing realization, or mix improvement. As a result, investors will focus on order intake, backlog conversion, and commentary around capital-equipment demand to assess whether the first-quarter cadence sets up a realistic path toward the annual target or points to a “back-half weighted” execution profile requiring stronger second-half ramps.

The company’s net profit margin of 4.49% last quarter provides a rough reference for this quarter’s profitability envelope. If adjusted EPS lands near 0.82 on a 310.51 million US dollar revenue base, the implied non-GAAP earnings yield per sales dollar remains steady relative to the prior-year quarter, reflecting that lower revenue and EBIT are being partially offset by cost actions and mix. Within operating expenses, any incremental investment to support product rollouts or post-sale service could mute flow-through, whereas better utilization of an expanding installed base would help protect margins. Commentary on procurement efficiencies and manufacturing throughput will therefore be a central swing factor for how investors interpret EBIT and the sustainability of adjusted EPS.

Most promising product and segment signals this quarter

General Surgery is positioned as the most scrutinized and potentially promising contributor this quarter given its scale within the portfolio and its direct linkage to high-usage procedure categories. In the previous quarter, General Surgery represented approximately 217.21 million US dollars of revenue on a 58% mix, anchoring the company’s 7.88% total revenue growth year over year and demonstrating solid throughput. For the upcoming print, the quality of General Surgery growth—unit volumes, average selling prices, and geographic breadth—will be as important as the absolute number, because it informs both margin trajectory and the durability of demand in recurring consumables tied to existing equipment placements.

Product-level execution remains in focus. Investors are monitoring utilization trends and post-sale attachment rates that drive recurring revenue within General Surgery, which can stabilize performance even if capital placement cycles moderate. Within that context, the pathway to convert an expanded installed base into higher recurring revenues is a core thesis that could allow the segment to outgrow consolidated top line later in the year. Should pricing hold and logistics remain disciplined, the segment’s contribution margin can meaningfully support consolidated EBIT resilience even if the overall revenue base is temporarily softer.

Orthopedic Surgery, at roughly 155.99 million US dollars last quarter on a 42% mix, remains integral to the multi-segment model and can provide incremental upside if case volumes and procedure intensity hold up. For the first quarter specifically, watch for clarity on case-seasonality patterns and whether operational efficiencies in instrument sets, repair kits, and disposable lines can offset any near-term variability in elective scheduling. Even modest improvements in throughput and order fulfillment can translate into better working capital turns, enhancing cash conversion—an element that investors often reward when growth is flattish.

Key stock-price swing factors this quarter

First, AirSeal-related performance and execution commentary are likely to be a central narrative driver. The stock has faced waves of caution tied to perceptions of uneven execution and questions around near-term catalysts, and any update on utilization, reliability, and the pipeline of new accounts could recalibrate sentiment. If management provides data points that affirm healthy usage patterns and stronger order visibility, it would counterbalance the conservative tone embedded in some ratings; conversely, equivocal messaging could reinforce a wait-and-see posture and keep valuation tethered to a hold-like framework.

Second, portfolio shaping and the recent divestiture activity feed directly into revenue composition and outlook confidence. In March 2026, the company completed a transaction to carve out selected product lines within its digestive portfolio, a move consistent with an effort to tighten focus on core areas. While the divested assets represented a discrete revenue contribution historically, the simplification can improve strategic clarity and allow resources to concentrate on higher-return opportunities. In the near term, the trade-off is that the consolidated top line may exhibit a slight reset until momentum from the core platforms fills the gap; how the first-quarter run-rate aligns with the full-year plan will therefore be interpreted as a litmus test of the redeployment strategy.

Third, the translation from revenue to earnings in the quarter will hinge on operating discipline and cost containment. With EBIT modeled at 38.21 million US dollars (down 3.54% year over year) and adjusted EPS modeled essentially flat year over year, small variances in gross-to-operating expense ratios can materially impact EPS delivery. Watch for explicit updates on procurement savings, logistics costs, and productivity in manufacturing. Given the prior quarter’s 47.26% gross margin, indications that price/mix or efficiency actions can defend that zone would bolster confidence in the annual EPS range. On the other hand, any unexpected input cost creep or adverse mix shift could place the burden on operating expense restraint, raising questions about the balance between growth investments and near-term profitability.

Finally, full-year guidance reconciliation is likely to be a focal point. With mid-range revenue guidance implying an average quarterly run-rate above the first-quarter consensus, the call needs to articulate either specific second-half catalysts or clear operational drivers that bridge the gap. Investors will pay particular attention to cadence across segments, onboarding of new accounts, and whether the order funnel and backlog conversion support a progressive step-up in subsequent quarters. Confirmation that demand signals are firm and that operational execution is tracking internal milestones would help validate the plan even if the first quarter arrives in line with subdued top-line expectations.

Analyst Opinions

The balance of opinions skews cautious. In mid-March, Piper Sandler downgraded Conmed to neutral from overweight and cut its price target to 39 US dollars, citing a lack of near-term catalysts and ongoing concerns tied to AirSeal performance and prior execution missteps. That view aligns with a broader hold-leaning stance reflected in recent months, with muted upside expectations embedded in targets and commentary. Given the absence of notable bullish pre-announcement calls in the monitored period, the majority signal into this report is cautious-to-bearish.

Piper Sandler’s framing connects directly to near-term risk-reward: without clear evidence of accelerating order intake or a step-up in utilization for key platforms, the pathway to re-rate the shares appears limited in the short run. Their lowered target effectively discounts a slower start to the year relative to full-year ambitions and assumes incremental proof points will be needed to close the gap between first-quarter consensus revenue of 310.51 million US dollars and the annual run-rate implied by guidance. The emphasis on AirSeal underscores that product-level consistency and commercial traction remain core to sentiment; acknowledging this, investors will parse not just the revenue print but also qualitative color on account additions, reliability metrics, and cross-sell progress.

The downgrade’s timing, ahead of the earnings date, places a premium on the company’s ability to demonstrate stable margins while defending the top line. If adjusted EPS of 0.82 is achieved with clean quality—i.e., not overly reliant on one-time expense timing—Piper Sandler’s concerns could be partly offset. However, if EBIT of 38.21 million US dollars and the top line both lean toward the lower end of internal cadences, the cautious stance gains reinforcement, particularly against a backdrop where the prior quarter printed a 47.26% gross margin and 4.49% net margin that set a high bar for consistency. The skeptical case further posits that portfolio simplification near term may cap reported growth while the benefits from strategic focus accrue over a longer horizon, reinforcing a wait-and-see posture.

In assessing what could challenge this majority-cautious view, the bar is straightforward: evidence of stronger unit volumes in General Surgery, steadier ordering in Orthopedic Surgery, firmer visibility on backlog conversion, and an articulation of second-half drivers that credibly bridge from a 310.51 million US dollar first-quarter base to the full-year guidance range. If management indicates that mix and procurement efficiencies can protect gross margin near the prior quarter’s 47.26% and that operating expense intensity can be contained without stalling commercial momentum, some sell-side caution could unwind. In the interim, the prevailing analyst stance remains anchored in prudence, with the earnings release and management commentary serving as the necessary validation points to recalibrate expectations.